canakinumab
Pronunciation: kan-ah-KIN-oo-mab
A fully human monoclonal antibody targeting interleukin-1β, used in pediatric autoinflammatory and rheumatic diseases.
Full Definition
Canakinumab is a fully human monoclonal antibody that specifically targets and neutralizes interleukin-1β (IL-1β), a key pro-inflammatory cytokine. It is FDA-approved for treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, and tumor necrosis factor receptor-associated periodic syndrome. The drug is administered subcutaneously every 4-8 weeks, with dosing based on body weight in pediatric patients. Common monitoring includes assessment for infection risk and injection site reactions.
Usage
Usage note: Brand name Ilaris should be capitalized; distinguish from other IL-1 inhibitors.
In Context
- "The patient showed complete resolution of fever episodes after starting canakinumab therapy." — Follow-up visit note
- "Canakinumab dosing was adjusted to 150 mg every 8 weeks based on the child's weight and clinical response." — Treatment modification note